Search results
Results from the WOW.Com Content Network
(Reuters) -The U.S. Food and Drug Administration has approved ARS Pharmaceuticals' nasal spray as the first needle-free emergency treatment for potentially fatal allergic reactions. The spray ...
The nasal spray will officially hit the market in eight weeks. ARS Pharmaceuticals is reportedly planning to file for FDA approval for a lower-dose version of Neffy, which would work for children ...
U.S. health officials on Friday approved a nasal spray to treat severe allergic reactions, the first needle-free alternative to shots like EpiPen. The Food and Drug Administration said it approved ...
U.S. health officials on Friday approved a nasal spray to treat severe allergic reactions, the first needle-free alternative to shots like EpiPen. The Food and Drug Administration said it approved the spray from drugmaker ARS Pharmaceuticals Inc. as an emergency treatment for adults and older children experiencing life-threatening allergic ...
The Food and Drug Administration approved a new nasal spray Friday as the first needle-free emergency treatment for potentially fatal allergic reactions.. The spray, which is made by ARS ...
The US Food and Drug Administration approved the first nasal spray epinephrine drug for severe allergic reactions known as anaphylaxis, providing a needle-free alternative to EpiPens and similar ...
Nalmefene, sold under the brand name Revex among others, is a medication that is used in the treatment of opioid overdose and alcohol dependence. [2] [3] Nalmefene belongs to the class of opioid antagonists and can be taken by mouth, administered by injection, or delivered through nasal administration.
Last week the FDA approved Neffy, an epinephrine nasal spray, for use in emergency allergic reactions for kids and adults. Retired allergist at the Northwest Asthma & Allergy Center Paul Williams ...